October 14th, 2013
Nicholas Bergfeld wonders what it will take to convince the medical community and the government that switching from hydrochlorothiazide to chlorthalidone is effective, economical, and life-saving for patients.
March 25th, 2013
This week’s topics include the effect of aliskiren on postdischarge mortality and readmissions among those hospitalized for HF, PFO closure, and more.
December 20th, 2011
After more than 20 years, the benefits of antihypertensive therapy are still evident, according to a new paper published in JAMA. John Kostis and colleagues performed a 22-year follow-up study on patients enrolled between 1985 and 1988 in the Systolic Hypertension in the Elderly Program (SHEP) trial. In 1991, SHEP found that low-dose chlorthalidone in 4736 elderly patients with isolated […]